Epidemiology and Outcome of Ventilator-associated Pneumonia Among Critically Ill COVID-19 Patients

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04372576

Enrollment

Registered

2020-05-04

Start date

2020-04-16

Completion date

2020-08-31

Last updated

2020-05-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Corona Virus Infection, Ventilator Associated Pneumonia

Brief summary

The aim of this study is to determine the risk factors for development of ventilator-associated pneumonia (VAP) and to identify the prognostic factors of VAP among Coronavirus Disease 2019 (CoViD-19) patients. We hypothesized that CoViD-19 serves as a high risk factor for the development of VAP and it affects clinical outcome measures negatively.

Detailed description

Coronavirus Disease 2019 (CoViD-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) became a pandemic affecting thousands of individuals worldwide. A considerable proportion of CoViD-19 patients require admission to the intensive care unit (ICU), although limited data are available on their clinical characteristics and course. The results of retrospective studies indicate older age, presence of comorbidies and secondary infections as predictors of mortality among this population. Further evaluation regarding ICU clinical course and predictors of mortality is needed. The aim of this study is to determine the risk factors for development of VAP and to identify the prognostic factors of VAP among CoViD-19 patients.

Interventions

DIAGNOSTIC_TESTAssessment of ventilator-associated pneumonia criteria

Diagnosis of ventilator-associated pneumonia is based upon the routine daily clinical and laboratory parameters.

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Critically ill individuals diagnosed with PCR confirmed CoViD-19 disease * Started mechanical ventilation for \> 48 hours * Informed consent signed by the patient or authorised representative

Exclusion criteria

* Participation in an interventional trial aiming nosocomial infections * refused informed consent

Design outcomes

Primary

Measure	Time frame
28-day all-cause mortality	at study completion, anticipated 5 months

Secondary

Measure	Time frame
Days of mechanical ventilation	average time frame expected 2-3 weeks
ICU length-of-stay	average time frame expected 3-4 weeks
Antibiotic utilization	average time frame expected 3-4 weeks (at discharge from ICU)
Ventilator-associated pneumonia rate	at study completion, anticipated 5 months

Countries

Hungary

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026